Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare Biotechnology
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Lipocine Receives Complete Response Letter for TLANDO(TM) from U.S. FDA

PR Newswire November 11, 2019

Lipocine to Present at the B. Riley NASH Symposium

PR Newswire October 14, 2019

Lipocine to Present at the H.C. Wainwright 3rd Annual NASH Investor Conference

PR Newswire October 10, 2019

Lipocine To Present LPCN 1144 Poster Of Distinction At The Liver Meeting® 2019

PR Newswire October 1, 2019

First Biopsy Confirmed Nash Patient Dosed In Lipocine LiFT Study Of LPCN 1144

PR Newswire September 30, 2019

Lipocine Announces Presentations at the 20th Annual Fall Meeting of the Sexual Medicine Society of North America

PR Newswire September 23, 2019

Lipocine to Participate in the Oppenheimer & Co. Fall Summit Focused on Specialty Pharma, Rare Disease & Gene Therapy

PR Newswire September 16, 2019

Lipocine Announces Trial Date in Lipocine's Infringement Lawsuit Against Clarus Therapeutics and Will Seek a Permanent Injunction

PR Newswire August 27, 2019

Lipocine Announces Second Quarter 2019 Financial and Operational Results

PR Newswire August 7, 2019

Lipocine to Present at the Canaccord Genuity 39th Annual Growth Conference

PR Newswire July 30, 2019

Lipocine Receives FDA Clearance for Clinical Testing its NASH Candidate, LPCN 1144, in Expanded Target Population

PR Newswire July 23, 2019

Lipocine Set To Join Russell Microcap® Index

PR Newswire June 25, 2019

Lipocine Announces TLANDO(TM) NDA PDUFA Action Date of November 9, 2019

PR Newswire May 14, 2019

Lipocine Announces First Quarter 2019 Financial and Operational Results

PR Newswire May 8, 2019

Lipocine Seeks Injunction Against the Marketing of Clarus Therapeutics' JATENZO® for Testosterone Replacement Therapy

PR Newswire April 3, 2019

Lipocine Announces ABPM Labeling Study Results Consistent with Recently Approved Testosterone Replacement Therapy

PR Newswire March 27, 2019

Lipocine Late-Breaker Presentation at EASL Meeting to Detail LPCN 1144 MRI-PDFF Based Clinical Results on Reduction of Liver Fat and Key Serum Biomarkers

PR Newswire March 26, 2019

Lipocine to Participate at the ROTH Battle of the NASH Thrones Spring Investor Conference

PR Newswire March 21, 2019

Lipocine Announces Presentation Highlighting Therapeutic Potential of LPCN 1144 in NAFLD and NASH Selected for ENDO 2019

PR Newswire March 14, 2019

48 Stocks Moving In Wednesday's Mid-Day Session

Benzinga.com  March 13, 2019